Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

941 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling.
Ungefroren H, Künstner A, Busch H, Franzenburg S, Luley K, Viol F, Schrader J, Konukiewitz B, Wellner UF, Meyhöfer SM, Keck T, Marquardt JU, Lehnert H. Ungefroren H, et al. Among authors: schrader j. Int J Mol Sci. 2022 Dec 14;23(24):15868. doi: 10.3390/ijms232415868. Int J Mol Sci. 2022. PMID: 36555512 Free PMC article.
Cancer-Associated Fibroblasts Induce Proliferation and Therapeutic Resistance to Everolimus in Neuroendocrine Tumors through STAT3 Activation.
Amin T, Viol F, Krause J, Fahl M, Eggers C, Awwad F, Schmidt B, Benten D, Ungefroren H, Fraune C, Clauditz TS, Sauter G, Izbicki JR, Lohse AW, Huber S, Schrader J. Amin T, et al. Among authors: schrader j. Neuroendocrinology. 2023;113(5):501-518. doi: 10.1159/000528539. Epub 2022 Dec 6. Neuroendocrinology. 2023. PMID: 36473454
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells.
von Hessert-Vaudoncourt C, Lelek S, Geisler C, Hartung T, Bröker V, Briest F, Mochmann L, Jost-Brinkmann F, Sedding D, Benecke J, Freitag H, Wolfshöfer S, Lammert H, Nölting S, Hummel M, Schrader J, Grabowski P. von Hessert-Vaudoncourt C, et al. Among authors: schrader j. Front Pharmacol. 2024 Feb 5;15:1308686. doi: 10.3389/fphar.2024.1308686. eCollection 2024. Front Pharmacol. 2024. PMID: 38375032 Free PMC article.
Author Correction: Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.
Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TPF, Siegel DL, Schrader J, Metz DC, June CH, Hua X. Feng Z, et al. Among authors: schrader j. Nat Cancer. 2024 Apr;5(4):691. doi: 10.1038/s43018-024-00766-5. Nat Cancer. 2024. PMID: 38605236 No abstract available.
Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies.
April-Monn SL, Kirchner P, Detjen K, Bräutigam K, Trippel MA, Grob T, Statzer C, Maire RS, Kollàr A, Chouchane A, Kunze CA, Horst D, Sadowski MC, Schrader J, Marinoni I, Wiedenmann B, Perren A. April-Monn SL, et al. Among authors: schrader j. NPJ Precis Oncol. 2024 Mar 1;8(1):59. doi: 10.1038/s41698-024-00549-2. NPJ Precis Oncol. 2024. PMID: 38429350 Free PMC article.
941 results